Stivarga (regorafenib)

pCPA File Number: 23387

Negotiation Status:

Active Negotiation

Indication(s):

For the treatment of metastatic osteosarcoma in patients who received at least 1 prior line of therapy.

Sponsor/Manufacturer:

Bayer Inc.

CDA-AMC Project Number:

PX0374-000

pCPA Engagement Letter Issued:

2025-10-21

Negotiation Process Concluded:

Not Applicable